[1]
|
沈田, 吴小川. 系统性红斑狼疮: 从发病机制到新型靶向治疗[J]. 协和医学杂志, 2023, 14(2): 234-240.
|
[2]
|
Huo, R., Huang, X., Yang, Y., et al. (2023) Potential Use of Janus Kinase Inhibitors in the Treatment of Systemic Lupus Erythematosus. Journal of Inflammation Research, 16, 1471-1478. https://doi.org/10.2147/JIR.S397639
|
[3]
|
中华医学会风湿病学分会, 国家皮肤与免疫疾病临床医学研究中心, 中国系统性红斑狼疮研究协作组. 2020中国系统性红斑狼疮诊疗指南[J]. 中华内科杂志, 2020, 59(3): 172-185.
|
[4]
|
Kariniemi, S., Rantalaiho, V., Virta, L.J., et al. (2022) Malignancies among Newly Diagnosed Systemic Lupus Erythematosus Patients and Their Survival. Lupus, 31, 1750-1758. https://doi.org/10.1177/09612033221131501
|
[5]
|
Gürsoy, V., Sadri, S. and Ermurat, S. (2023) Evaluation of Acquired and Hereditary Risk Factors for the Development of Thromboembolism in Patients with Systemic Lupus Erythematosus. Blood Coagulation & Fibrinolysis, 34, 478-486. https://doi.org/10.1097/MBC.0000000000001253
|
[6]
|
沈南, 赵毅, 段利华, 等. 系统性红斑狼疮诊疗规范[J]. 中华内科杂志, 2023, 62(7): 775-784.
|
[7]
|
张莹莹, 王世颖, 束庆, 等. 靶向B淋巴细胞治疗系统性红斑狼疮的生物制剂: 贝利尤单抗与泰它西普[J]. 中南药学, 2022, 20(10): 2356-2362.
|
[8]
|
单慧亭, 孟岩, 陈迹, 等. 糖皮质激素联合免疫抑制剂致系统性红斑狼疮患者感染预测模型[J]. 中国医院药学杂志, 2023, 43(14): 1588-1592.
|
[9]
|
Lourdudoss, C., Hafström, I., Frostegård, J., et al. (2016) The Association between Diet and Glucocorticoid Treatment in Patients with SLE. Lupus Science & Medicine, 3, e000135. https://doi.org/10.1136/lupus-2015-000135
|
[10]
|
Zou, Y.F., Xu, J.H., Gu, Y.Y., et al. (2016) Single Nucleotide Polymorphisms of HSP90AA1 Gene Influence Response of SLE Patients to Glucocorticoids Treatment. Springerplus, 5, Article No. 222. https://doi.org/10.1186/s40064-016-1911-4
|
[11]
|
尤含笑. 系统性红斑狼疮发生静脉血栓栓塞风险预测模型的建立及免疫球蛋白G糖基化标志物的研究[D]: [博士学位论文]. 北京: 北京协和医学院, 2020.
|
[12]
|
Fillatreau, S., Manfroi, B. and Dörner, T. (2021) Toll-Like Receptor Signalling in B Cells during Systemic Lupus Erythematosus. Nature Reviews Rheumatology, 17, 98-108. https://doi.org/10.1038/s41584-020-00544-4
|
[13]
|
Fan, Y., Gao, D. and Zhang, Z. (2022) Telitacicept, a Novel Humanized, Recombinant TACI-Fc Fusion Protein, for the Treatment of Systemic Lupus Erythematosus. Drugs Today (Barc), 58, 23-32. https://doi.org/10.1358/dot.2022.58.1.3352743
|
[14]
|
林千祺, 许夏雨, 邢诒喜, 等. 泰它西普联合标准方案治疗III-V型活动性狼疮肾炎临床观察[J]. 中国药业, 2023, 32(12): 97-100.
|
[15]
|
陈燕, 张雨婷, 何雨谣, 等. 泰它西普与贝利尤单抗在狼疮肾炎治疗中的应用效果及安全性比较[J]. 山东医药, 2024, 64(5): 74-77.
|
[16]
|
Salazar-Camarena, D.C., Ortíz-Lazareno, P., Marín-Rosales, M., et al. (2019) BAFF-R and TACI Expression on CD3 T Cells: Interplay among BAFF, APRIL and T Helper Cytokines Profile in Systemic Lupus Erythematosus. Cytokine, 114, 115-127. https://doi.org/10.1016/j.cyto.2018.11.008
|
[17]
|
Shi, F., Xue, R., Zhou, X., et al. (2021) Telitacicept as a BLyS/APRIL Dual Inhibitor for Autoimmune Disease. Immunopharmacology and Immunotoxicology, 43, 666-673. https://doi.org/10.1080/08923973.2021.1973493
|
[18]
|
Sun, W., Yan, S., Yang, C., et al. (2022) Mesenchymal Stem Cells-Derived Exosomes Ameliorate Lupus by Inducing M2 Macrophage Polarization and Regulatory T Cell Expansion in MRL/Lpr Mice. Immunological Investigations, 51, 1785-1803. https://doi.org/10.1080/08820139.2022.2055478
|
[19]
|
Marinho, A., Delgado, A.J., Fortuna, J., et al. (2023) Biological Therapy in Systemic Lupus Erythematosus, Antiphospholipid Syndrome, and Sjögren’s Syndrome: Evidence-and Practice-Based Guidance. Frontiers in Immunology, 14, Article ID: 1117699. https://doi.org/10.3389/fimmu.2023.1117699
|
[20]
|
Lou, H., Ling, G.S. and Cao, X. (2022) Autoantibodies in Systemic Lupus Erythematosus: From Immunopathology to Therapeutic Target. Journal of Autoimmunity, 132, Article ID: 102861. https://doi.org/10.1016/j.jaut.2022.102861
|
[21]
|
Savelli, S.L., Roubey, R., Kitzmiller, K.J., et al. (2019) Opposite Profiles of Complement in Antiphospholipid Syndrome (APS) and Systemic Lupus Erythematosus (SLE) among Patients with Antiphospholipid Antibodies (aPL). Frontiers in Immunology, 10, Article No. 885. https://doi.org/10.3389/fimmu.2019.00885
|
[22]
|
Pons-Estel, G.J., Andreoli, L., Scanzi, F., et al. (2017) The Antiphospholipid Syndrome in Patients with Systemic Lupus Erythematosus. Journal of Autoimmunity, 76, 10-20. https://doi.org/10.1016/j.jaut.2016.10.004
|
[23]
|
Erton, Z.B. and Erkan, D. (2022) Treatment Advances in Antiphospholipid Syndrome: 2022 Update. Current Opinion in Pharmacology, 65, Article ID: 102212. https://doi.org/10.1016/j.coph.2022.102212
|
[24]
|
Wang, Y., Lin, X., Wu, Q., et al. (2015) Thrombophilia Markers in Patients with Recurrent Early Miscarriage. Clinical Laboratory, 61, 1787-1794. https://doi.org/10.7754/Clin.Lab.2015.150603
|
[25]
|
Cocco, C., Manca, E., Corda, G., et al. (2023) Brain-Reactive Autoantibodies in Neuropsychiatric Systemic Lupus Erythematosus. Frontiers in Immunology, 14, Article ID: 1157149. https://doi.org/10.3389/fimmu.2023.1157149
|
[26]
|
盛良驹. Anti-β2GPI/β2GPI复合物诱导促凝和炎性分子表达及血栓形成机制研究[D]: [博士学位论文]. 镇江: 江苏大学, 2019.
|
[27]
|
Drosos, G.C., Vedder, D., Houben, E., et al. (2022) EULAR Recommendations for Cardiovascular Risk Management in Rheumatic and Musculoskeletal Diseases, Including Systemic Lupus Erythematosus and Antiphospholipid Syndrome. Annals of the Rheumatic Diseases, 81, 768-779. https://doi.org/10.1136/annrheumdis-2021-221733
|
[28]
|
李延辉, 谢敏如, 叶仕英, 等. 结肠癌及癌前病变中APRIL和Caspase-3蛋白的表达及其作用[J]. 中国医药导报, 2016, 13(14): 92-95.
|
[29]
|
Samy, E., Wax, S., Huard, B., et al. (2017) Targeting BAFF and APRIL in Systemic Lupus Erythematosus and Other Antibody-Associated Diseases. International Reviews of Immunology, 36, 3-19. https://doi.org/10.1080/08830185.2016.1276903
|
[30]
|
Bag-Ozbek, A. and Hui-Yuen, J.S. (2021) Emerging B-Cell Therapies in Systemic Lupus Erythematosus. Therapeutics and Clinical Risk Management, 17, 39-54. https://doi.org/10.2147/TCRM.S252592
|
[31]
|
La Cava, A. (2013) Targeting the BLyS-APRIL Signaling Pathway in SLE. Clinical Immunology, 148, 322-327. https://doi.org/10.1016/j.clim.2012.11.010
|
[32]
|
Fairfax, K., Mackay, I.R. and Mackay, F. (2012) BAFF/BLyS Inhibitors: A New Prospect for Treatment of Systemic Lupus Erythematosus. IUBMB Life, 64, 595-602. https://doi.org/10.1002/iub.1046
|
[33]
|
Stadanlick, J.E., Kaileh, M., Karnell, F.G., et al. (2008) Tonic B Cell Antigen Receptor Signals Supply an NF-KappaB Substrate for Prosurvival BLyS Signaling. Nature Immunology, 9, 1379-1387. https://doi.org/10.1038/ni.1666
|
[34]
|
Möckel, T., Basta, F., Weinmann-Menke, J., et al. (2021) B Cell Activating Factor (BAFF): Structure, Functions, Autoimmunity and Clinical Implications in Systemic Lupus Erythematosus (SLE). Autoimmunity Reviews, 20, Article ID: 102736. https://doi.org/10.1016/j.autrev.2020.102736
|
[35]
|
Zouali, M. and Uy, E.A. (2013) Belimumab Therapy in Systemic Lupus Erythematosus. BioDrugs, 27, 225-235. https://doi.org/10.1007/s40259-013-0031-8
|
[36]
|
Arbitman, L., Furie, R. and Vashistha, H. (2022) B Cell-Targeted Therapies in Systemic Lupus Erythematosus. Journal of Autoimmunity, 132, Article ID: 102873. https://doi.org/10.1016/j.jaut.2022.102873
|
[37]
|
Hubben, A. and McCrae, K.R. (2023) How to Diagnose and Manage Antiphospholipid Syndrome. Hematology, ASH Education Program, 2023, 606-613. https://doi.org/10.1182/hematology.2023000493
|
[38]
|
张晓宇, 舒强. 生物制剂联合治疗在抗磷脂综合征中的应用[J]. 山东第一医科大学(山东省医学科学院)学报, 2023, 44(12): 881-889.
|
[39]
|
杨佳, 高洁, 赵文静, 等. 泰它西普在IgA肾病和狼疮性肾炎中的研究进展[J]. 中国现代医学杂志, 2022, 32(19): 51-56.
|
[40]
|
Myette, J.R., Kano, T., Suzuki, H., et al. (2019) A Proliferation Inducing Ligand (APRIL) Targeted Antibody Is a Safe and Effective Treatment of Murine IgA Nephropathy. Kidney International, 96, 104-116. https://doi.org/10.1016/j.kint.2019.01.031
|
[41]
|
Aguirre-Valencia, D., Ríos-Serna, L.J., Posso-Osorio, I., et al. (2020) Expression of BAFF, APRIL, and Cognate Receptor Genes in Lupus Nephritis and Potential Use as Urinary Biomarkers. Journal of Translational Autoimmunity, 3, Article ID: 100027. https://doi.org/10.1016/j.jtauto.2019.100027
|
[42]
|
Frostegård, J. (2023) Systemic Lupus Erythematosus and Cardiovascular Disease. Journal of Internal Medicine, 293, 48-62. https://doi.org/10.1111/joim.13557
|
[43]
|
Tsuchida, Y., Shoda, H., Sawada, T., et al. (2023) Role of Autotaxin in Systemic Lupus Erythematosus. Frontiers in Medicine (Lausanne), 10, Article ID: 1166343. https://doi.org/10.3389/fmed.2023.1166343
|
[44]
|
Bhaskar, L. and Nagaraju, G.P. (2019) Clinical and Immunogenetic Aspects of Systemic Lupus Erythematosus. Critical Reviews™ in Immunology, 39, 343-360. https://doi.org/10.1615/CritRevImmunol.2020033247
|